Benzene Ring Containing Patents (Class 514/576)
-
Publication number: 20090253798Abstract: Disclosed are new colchicine solid complexes, methods of making the solid complexes as well as formulations prepared therefrom and uses thereof.Type: ApplicationFiled: April 2, 2009Publication date: October 8, 2009Inventors: Tong Sun, David Jonaitis, Stephan D. Parent
-
Publication number: 20090202457Abstract: The present invention relates to an exfoliating composition. The composition comprises a mixture. The mixture comprises phenolsulfonic acid, guaiacolsulfonic acid, and optionally sulfosalicylic acid and citric acid.Type: ApplicationFiled: March 9, 2009Publication date: August 13, 2009Inventor: Michael Basara
-
Patent number: 7572798Abstract: The present invention relates to a series of new chemical agents that demonstrate anti-tumor activity. More particularly, the present invention relates to molecules, referred to as “combi-molecules”, that combine two major mechanisms of anti-tumor action. A combi-molecule is capable of degrading to a ligand involved in cell signaling pathways and to an agent capable of damaging DNA. More specifically, the present invention relates to molecules capable of blocking epidermal growth factor receptor (EGFR) mediated signal transduction and capable of damaging DNA. The present invention also relates to a general method of synthesis of these combi-molecules.Type: GrantFiled: February 26, 2002Date of Patent: August 11, 2009Assignee: McGill UniversityInventors: Bertrand J. Jean-Claude, Fabienne Dudouit, Stephanie Matheson
-
Publication number: 20090176885Abstract: Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, polycystic ovary syndrome, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed.Type: ApplicationFiled: February 1, 2007Publication date: July 9, 2009Applicant: WELLSTAT THERAPEUTICS CORPORATIONInventors: Shalini Sharma, Reid W. von Borstel
-
Publication number: 20090124664Abstract: The present invention relates to selected (R)-arylalkylamino derivatives of formula (I), in which R, R1 and Ar are as defined in the claims. These compounds show a surprising potent inhibitory effect on C5a induced human PMN chemotaxis. The compounds of the invention absolutely lack of CXCL8 inhibitory activity. Said compounds are useful in the treatment of pathologies depending on the chemotactic activation of neutrophils and monocytes induced by the fraction C5a of the complement. In particular, the compounds of the invention are useful in the treatment of sepsis, psoriasis, rheumatoid arthritis, ulcerative colitis, acute respiratory distress syndrome, idiopathic fibrosis, glomerulonephritis and in the prevention and treatment of injury caused by ischemia and reperfusion.Type: ApplicationFiled: November 24, 2006Publication date: May 14, 2009Inventors: Marcello Allegretti, Alessio Moriconi, Andrea Aramini, Maria Candida Cesta, Andrea Beccari, Riccardo Bertini
-
Publication number: 20090111779Abstract: The invention describes compositions and methods of use for 2,5-dihydroxybenzene sulfonic acid compounds and pharmaceutically acceptable salts thereof. The invention provides methods for (a) treating skin cancer; (b) treating cancer of the organs; (c) treating leukemia; (d) improving the efficacy of chemotherapy, radiation therapy and/or cancer immunotherapy; (e) treating rosacea; and (f) treating psoriasis by administration of a composition comprising at least one 2,5-dihydroxybenzene sulfonic acid compound or a pharmaceutically acceptable salt thereof, and, optionally at least one therapeutic agent. Also disclosed are compositions comprising administration of at least one 2,5-dihydroxybenzene sulfonic acid compound, or a pharmaceutically acceptable salt thereof, and, at least one therapeutic agent.Type: ApplicationFiled: October 24, 2008Publication date: April 30, 2009Applicant: ACTION MEDICINES, S.L.Inventors: Pedro Cuevas Sanchez, Antonio Romero Garrido, Guillermo Gimenez Gallego, Serafin Valverde Lopez, Rosa Maria Lozano Puerto
-
Publication number: 20090105280Abstract: Pharmaceutical compositions comprising at least one compound of e.g. the formulas (Ie) and a pharmaceutically acceptable carrier which is useful in a medicine wherein the symbols and substituents have the following meaning —X— is e.g. and Y is e.g. or the pharmaceutically acceptable salts, esters or amides and prodrugs of the above identified compounds can be applied to modulate the in-vitro and in-vivo binding processes mediated by E-, P- or L-selectin binding.Type: ApplicationFiled: September 20, 2006Publication date: April 23, 2009Applicant: REVOTAR BIOPHARMACEUTICALS AGInventors: Ewald M. Aydt, Remo Kranich
-
Publication number: 20090088477Abstract: This invention provides novel salt and crystalline forms thereof of (?)4-(4-fluorophenyl)-7-[({5-[1-hydroxy-1-(trifluoromethyl)propyl]-1,3,4-oxadiazol-2-yl}amino)-methyl]-2H-chromen-2-one. The compounds are 5-LO inhibitors and are useful for treatment of conditions such as asthma, allergic rhinitis, COPD, and atherosclerosis.Type: ApplicationFiled: September 24, 2008Publication date: April 2, 2009Inventors: Francis Gosselin, Vicky Vydra
-
Publication number: 20090082454Abstract: The present application describes deuterium-enriched disufenton, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.Type: ApplicationFiled: August 21, 2008Publication date: March 26, 2009Applicant: PROTIA, LLCInventor: Anthony W. Czarnik
-
Patent number: 7482377Abstract: New pharmaceutical compositions for oral use containing diclofenac together with alkali metal bicarbonates in amounts of from 20 to 80 by weight with respect to diclofenac are described. These compositions are entirely palatable and free from any unpleasant taste or other, side effects; in particular, these formulations permit to obtain in human patients higher Cmax of the active principle and shorter Tmax together with a lower coefficient of variation.Type: GrantFiled: May 18, 2005Date of Patent: January 27, 2009Assignee: Kowa Pharmaceuticals America, Inc.Inventors: Alberto Reiner, Giorgio Reiner
-
Publication number: 20090018200Abstract: Novel uses of phenanthrenol compounds for improving the appearance and/or texture of the skin.Type: ApplicationFiled: July 14, 2008Publication date: January 15, 2009Applicant: L'OREALInventors: Claudie WILLEMIN, Geoffroy Remaut, Angeles Fonolla Moreno, Cyril Lemoine
-
Patent number: 7468446Abstract: The present invention relates to substituted heterocyclic compounds and compositions comprising a substituted heterocyclic compound. The present invention also relates to methods for preventing or treating various diseases and disorders by administering to a subject in need thereof one or more substituted heterocyclic compounds. In particular, the invention relates to methods for preventing or treating cancer or an inflammatory disorder by administering to a subject in need thereof one or more substituted heterocyclic compounds. The present invention further relates to articles of manufacture and kits comprising one or more substituted heterocyclic compounds.Type: GrantFiled: September 1, 2005Date of Patent: December 23, 2008Assignee: Celgene CorporationInventors: George W. Muller, Hon-Wah Man
-
Publication number: 20080293816Abstract: The invention relates to the use of 2,5-dihydroxybenzenesulfonic acid in the production of medicaments for the treatment of angiodependent diseases. More specifically, the invention relates to the use of the aforesaid compound and, in particular, the calcium and potassium salts thereof, for the treatment of two angiodependent diseases, which present a reduction in the apoptosis, namely cancer and psoriasis. The invention also discloses the antiproliferative, antimigratory, antiangiogenic and proapoptotic capacity of said family of compounds in non-quiescent cells. In addition, the invention details the potentiating effect of said compounds on known cytostatic medicines in the treatment of tumours and, specifically, on gliomas. The invention further relates to the therapeutic efficacy of said compounds, based on the combined antiproliferative, antiangiogenic and proapoptotic capacities thereof, in the treatment of chronic psoriatic plaques.Type: ApplicationFiled: February 16, 2005Publication date: November 27, 2008Inventors: Pedro Cuevas Sanchez, Antonio Romero Garrido, Guillermo Gimenez Gallego, Serafin Valverde Lopez, Rosa Maria Lozano Puerto
-
Publication number: 20080275125Abstract: A combination pharmaceutical composition for the treatment of pain including about 125 mg to about 150 mg ibuprofen and about 475 mg to about 500 mg paracetamol.Type: ApplicationFiled: July 7, 2005Publication date: November 6, 2008Applicant: AFT PHARMACEUTICALS LIMITEDInventor: Hartley Campbell Atkinson
-
Publication number: 20080269189Abstract: Compounds, compositions, and methods of avoiding edema while treating or preventing PPAR?-mediated diseases, including cancer, using derivatives and prodrugs are provided.Type: ApplicationFiled: March 21, 2006Publication date: October 30, 2008Inventors: Martin E. Sanders, David D. Karpf
-
Publication number: 20080206158Abstract: Benzoic acid ester compounds of formula (I): wherein R and R1-R5 have the meanings explained in the description, methods for producing them and use thereof in cosmetic, pharmaceutical, personal care and industrial preparations as sunscreens based on photochemical precursor properties of ultraviolet absorbers.Type: ApplicationFiled: March 20, 2006Publication date: August 28, 2008Applicant: Ferrer Internacional, S.A.Inventors: Ricardo Miralles, Santiago Nonell, Manuel M. Raga, Antonio Giuglietta, Jordi Teixido
-
Publication number: 20080188564Abstract: The present invention provides methods of protecting plants and other multicellular organisms from the parasitic activity of nematodes and insects. The methods use compounds, such as stilbene compounds, as nematicidal and insecticidal compounds, which act to alter the activity of one or more anion transporters in the nematodes and insects. Methods of screening for such compounds are also provided.Type: ApplicationFiled: November 29, 2005Publication date: August 7, 2008Inventors: Jeffrey R. Bloomquist, Edwin E. Lewis
-
Publication number: 20080167311Abstract: Novel compounds, and therapeutic methods, compositions and medicament related thereto are disclosed herein.Type: ApplicationFiled: November 13, 2007Publication date: July 10, 2008Inventors: David W. Old, Vinh X. Ngo, Wha-Bin Im
-
Publication number: 20080161308Abstract: Compounds of the formula (I): in which A, R1, R2, X, Y and Z are defined in the description, the processes for the preparation of these compounds, the uses thereof for the treatment of dyslipidaemia, atherosclerosis and diabetes, and the pharmaceutical compositions comprising them.Type: ApplicationFiled: December 22, 2005Publication date: July 3, 2008Inventors: Catherine Vidal, Nathalie Adje, Stephane Yvon, Jean Jacques Zeiller
-
Patent number: 7358262Abstract: The present invention relate to methods of identifying a genotype-selective agent. In certain embodiments, the invention relates to agents that are selectively toxic to engineered human tumorigenic cells.Type: GrantFiled: January 29, 2004Date of Patent: April 15, 2008Assignee: Whitehead Institute for Biomedical ResearchInventor: Brent R. Stockwell
-
Patent number: 7319096Abstract: This invention relates to novel compounds which are thyroid receptor ligands, preferably antagonists, and to methods for using such compounds in the treatment of cardiac and metabolic disorders, such as cardiac arrhythmias, thyrotoxicosis, subclinical hyperthyrodism and liver diseases.Type: GrantFiled: April 15, 2002Date of Patent: January 15, 2008Assignee: Karo Bio ABInventors: Johan Malm, Peter Brandt, Karin Edvinsson, Thomas Ericsson, Sandra Gordon
-
Patent number: 7291599Abstract: The invention relates to a process for the treatment of neurodegenerative diseases wherein mis-folded proteins accumulate in characteristic lesions and contribute substantially to a pathogenesis and to an inflammatory reaction magnifying the damage, by the isolated or joint effect of inhibitors of the alanyl amino peptidase (APN) and of the dipeptidyl peptidase N (DP IV). Our results show that the application of inhibitors of the above-referenced enzymes or of preparations and dosage forms containing such inhibitors is definitely suitable for a therapy and prevention of dementia diseases and conditions.Type: GrantFiled: August 11, 2004Date of Patent: November 6, 2007Assignee: Keyneurotek AGInventors: Frank Striggow, Peter Rohnert, Till Mack
-
Patent number: 7285572Abstract: The present invention provides a compound having a calcium-sensitive receptor antagonistic action, a pharmaceutical composition containing the compound, particularly a calcium receptor antagonist and a therapeutic drug for osteoporosis. A compound represented by the following formula (1), a pharmaceutically acceptable salt thereof or an optically active form thereof: wherein each symbol is as defined in the description.Type: GrantFiled: November 25, 2005Date of Patent: October 23, 2007Assignee: Japan Tobacco Inc.Inventors: Yuko Shinagawa, Teruhiko Inoue, Toshihiro Kiguchi, Taku Ikenogami, Naoki Ogawa, Takashi Nakagawa, Masanori Shindo, Yuki Soejima
-
Patent number: 7229969Abstract: Combination of inhibitors of dipeptidyl peptidase IV (DP IV) and enzymes having the same substrate specificity (DP IV-analogous enzymatic activity) and inhibitors of alanyl aminopeptidase (aminopeptidase N, APN) and of enzymes having the same substrate specificity (APN-analogous enzymatic activity) for a more than additive to superadditive inhibition for the treatment of arteriosclerosis, for the treatment of allergic reactions of the type I according to the Gell and Coombs classification and for the treatment of dermatological diseases with follicular and epidermal hyperkeratoses and an enhanced proliferation of keratinocytes.Type: GrantFiled: December 21, 2001Date of Patent: June 12, 2007Assignee: IMTM GmbHInventors: Siegfried Ansorge, Uwe Lendeckel, Klaus Neubert, Dirk Reinhold, Robert Vetter, Harald Gollnick
-
Patent number: 7141238Abstract: Exposure of human skin to ultraviolet (UV) radiation from the sun not only induces the production of enzymes (matrix metalloproteinases) that degrade collagen, but also inhibits the synthesis of new collagen by inhibiting the synthesis of procollagen. This UV-induced inhibition of the synthesis of collagen can be prevented by the topical application of a retinoid or c-JUN inhibitor to the skin prior to exposure to UV radiation.Type: GrantFiled: October 22, 2003Date of Patent: November 28, 2006Assignee: The Regents of the University of MichiganInventors: Gary J. Fisher, John J. Voorhees
-
Patent number: 7122580Abstract: This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention are useful as antagonists, or more preferably, partial antagonist of factor IX and thus, may be used to inhibit the intrinsic pathway of blood coagulation. The compounds are useful in a variety of applications including the management, treatment and/or control of diseases caused in part by the intrinsic clotting pathway utilizing factor IX. Such diseases or disease states include stroke, myocardial infarction, aneurysm surgery, and deep vein thrombosis associated with surgical procedures, long periods of confinement, and acquired or inherited pro-coagulant states.Type: GrantFiled: August 8, 2003Date of Patent: October 17, 2006Assignee: TransTech Pharma, Inc.Inventors: Adnan M. M. Mjalli, Robert C. Andrews, Xiao-Chuan Guo, Daniel Peter Christen, Devi Reddy Gohimmukkula, Guoxiang Huang, Robert Rothlein, Sameer Tyagi, Tripura Yaramasu, Christopher Behme
-
Patent number: 7109164Abstract: New thyroid receptor ligands are provided which have the general formula in which: X is —O—, —S—, —CH2—, —CO—, or —NH—; Y is —(CH2)n— where n is an integer from 1 to 5, or cis- or trans-ethylene; R1 is halogen, trifluoromethyl, or alkyl of 1 to 6 carbons or cycloalkyl of 3 to 7 carbons; R2 and R3 are the same or different and are hydrogen, halogen, alkyl of 1 to 4 carbons or cycloalkyl of 3 to 6 carbons, at least one of R2 and R3 being other than hydrogen; R4 is hydrogen or lower alkyl; R5 is hydrogen or lower alkyl; R6 is carboxylic acid, or esters or prodrugs; R7 is hydrogen or an alkanoyl or an aroyl. In addition, a method is provided for preventing, inhibiting or treating a disease associated with metabolism dysfunction or which is dependent upon the expression of a T3 regulated gene, wherein a compound as described above is administered in a therapeutically effective amount.Type: GrantFiled: August 30, 2004Date of Patent: September 19, 2006Assignee: Bristol-Myers Squibb CompanyInventors: Todd J. Friends, Denis E. Ryono, Minsheng Zhang
-
Patent number: 7037914Abstract: A peroxisome proliferator activated receptor regulator containing a carboxylic acid derivative of formula (I) (wherein all symbols are as defined in the specification), a non-toxic acid thereof or a hydrate thereof as active ingredient. Because of having an effect of regulating PPAR, a compound of formula (I) is useful as a hypoglycemic agent, a hypolipidemic agent, a preventive and/or a remedy for diseases associating metabolic disorders (diabetes, obesity, syndrome X, hypercholesterolemia, hyperlipoproteinemia, etc.), hyperlipemia, atherosclerosis, hypertension, circulatory diseases, overeating, coronary heart diseases, etc., an HDL cholesterol-elevating agent, an LDL cholesterol and/or VLDL cholesterol-lowering agent and a drug for relief from risk factors of diseases or syndrome X.Type: GrantFiled: September 23, 2002Date of Patent: May 2, 2006Assignee: Ono Pharmaceutical Co., Ltd.Inventors: Hisao Tajima, Yoshisuke Nakayama, Daikichi Fukushima
-
Patent number: 7019031Abstract: Oncoproteins such as Ras and RhoB are known to induce cell division in an unrestrained manner when such proteins are localized at the inner surface of a cancer cell membrane. The localization is effected by the prenylation reaction, whereby a hydrophobic group (e.g. a farnesyl group) is attached to the protein in the presence of an enzyme (e.g. farnesyl protein transferase). Deactivation of the prenylation enzyme through covalent modification can therefore ultimately result in the mitigation and/or cessation of cancer cell growth. Various prenylation inhibitors having the necessary structural groups to bond covalently, or essentially irreversibly, to the prenylation enzyme include carbonyl or thiocarbonyl compounds (or masked versions of these compounds) and alpha oxo-epoxides bonded to a hydrophobic, substrate-mimicking group. The carbonyl or thiocarbonyl compounds also contain a nucleofugal atom or group to enhance the tendency to form covalent bonds.Type: GrantFiled: October 23, 2001Date of Patent: March 28, 2006Assignee: The Arizona Disease Control Research CommissionInventors: Seth D. Rose, Scott R. Lefler, Steven R. Ottersberg, Ann Y. Kim, Karl J. Okolotowicz, Rosemarie F. Hartman
-
Patent number: 7014864Abstract: The present invention is directed to a formulation comprising a lipid-regulating agent dissolved in at least one structured lipid as the primary solvent medium for said agent. One or more emulsifiers may be added to the formulation.Type: GrantFiled: December 18, 1998Date of Patent: March 21, 2006Assignee: Abbott LaboratoriesInventors: John M. Lipari, Dawn M. Raymond, Tom Reiland
-
Patent number: 6984389Abstract: The present invention relates to methods of improving a treatment outcome comprising administering a heat shock protein (HSP) preparation or an ?-2-macroglobulin (?2M) preparation with a non-vaccine treatment modality. In particular, an HSP preparation or an ?2M preparation is administered in conjunction with a non-vaccine treatment modality for the treatment of cancer or infectious diseases. In the practice of the invention, a preparation comprising HSPs such as but not limited to, hsp70, hsp90 and gp96 alone or in combination with each other, noncovalently or covalently bound to antigenic molecules or ?2M, noncovalently or covalently bound to antigenic molecules is administered in conjunction with a non-vaccine treatment modality.Type: GrantFiled: December 16, 2002Date of Patent: January 10, 2006Assignee: University of Connecticut Health CenterInventor: Zihai Li
-
Patent number: 6982097Abstract: This invention relates to biocidal compositions and methods of using same. Also provided is a process for the manufacturing of a biocidal composition in the form of a tablet and a method of using the biocidal compositions for the disinfection of water that may contain microorganisms and biofilms.Type: GrantFiled: July 15, 2003Date of Patent: January 3, 2006Assignee: Sani-Care Salon Products, Inc.Inventors: Su Mingzhong, Long Truong Hoang, Linh Truong Hoang
-
Patent number: 6974595Abstract: New pharmaceutical compositions for oral use containing Diclofenac together with alkali metal bicarbonates in amounts of from 20 to 80 by weight with respect to Diclofenac are described. These compositions are entirely palatable and free from any unpleasant taste or other side effects; in particular, these formulations permit to obtain in human patients higher Cmax of the active principle and shorter Tmax together with a lower coefficient of variation.Type: GrantFiled: March 14, 2000Date of Patent: December 13, 2005Assignee: ProEthic Pharmaceuticals, Inc.Inventors: Alberto Reiner, Giorgio Reiner
-
Patent number: 6962714Abstract: The present invention relates to antimicrobial compositions including a critical, near critical, or supercritical (densified) fluid and an antimicrobial agent, to methods of forming these compositions, and to methods employing these compositions. An antimicrobial agent can be generated in the presence of a densified fluid, for example, by reacting an oxidizing agent with a precursor to the antimicrobial agent.Type: GrantFiled: August 6, 2002Date of Patent: November 8, 2005Assignee: Ecolab, Inc.Inventors: Robert D. P. Hei, Keith E. Olson, Robert J. Ryther, Richard K. Staub
-
Patent number: 6962774Abstract: A tissue of a multicellular organism is gradually dried during cultivation. After the tissue has been completely dehydrated, water is added to the tissue for its recovery. The tissue of the multicellular organism is submerged in an insect body fluid medium treated with heat, and dried for 48 hours or more.Type: GrantFiled: September 11, 2003Date of Patent: November 8, 2005Assignees: National Institute of Agrobiological SciencesInventors: Takashi Okuda, Masahiko Watanabe, Takahiro Kikawada
-
Patent number: 6953786Abstract: Disclosed are methods for treating, preventing, or inhibiting cancer in a subject comprising administering at least one polyphenolic compound and at least one inhibitor of reactive oxygen species to the subject. The polyphenolic compound may be derived or isolated from plants. In some embodiments, the polyphenolic compound is a flavonoid. In other embodiments, the polyphenolic compound is a non-flavonoid. Other methods and kits are also disclosed as well as pharmaceutical compositions.Type: GrantFiled: October 1, 2002Date of Patent: October 11, 2005Assignees: The Regents of the University of California, The United States of America as represented by the Department of Veterans' AffairsInventors: Stephen J. Pandol, Anna Gukovskaya
-
Patent number: 6943194Abstract: A newly discovered antineoplastic compound denominated “phenstatin” is herein described as are synthetic methods for producing phenstatin and the active prodrug thereof. Phenstatin was converted to the sodium phosphate prodrug (3d) by a dibenzylphosphite phosphorylation and subsequent hydrogenolysis sequence 3b?3c?3d. Phenstatin (3b) was found to be a potent inhibitor of tubulin polymerization and the binding of colchicine to tubulin comparable to combretastatin A-4 (1b).Type: GrantFiled: January 9, 1999Date of Patent: September 13, 2005Assignee: Arizona Board of Regents, acting for and on behalf of Arizona State UniversityInventors: George R. Pettit, Brian Toki
-
Patent number: 6919072Abstract: Chronological aging of human skin can be delayed with the topical application of an MMP inhibitor, preferably a retinoid (an indirect MMP inhbitor); retinoids also normalize procollagen biosynthesis. Chronological aging, or natural aging, is evidenced in elderly (80+ years old) skin by increased MMP levels and decreased procollagen levels when compared with younger individuals. Prophylactic treatment of not yet chronologically-aged skin with a retinoid both inhibits degradation of dermal collagen and restores procollagen synthesis. Biopsied sections from elderly skin show that a single treatment of chronologically-aged skin with a retinoid can increase epidermal thickness, improve the dermal collagen density, and promote the formation of rete pegs and dermal papillae. Such benefits are helpful in preventing bruising, tearing, and ulceration of elderly skin. Accordingly, prophylactic treatment begun much earlier in life with an MMP inhibitor and/or a retinoid delays the onset of such symptoms.Type: GrantFiled: June 10, 2003Date of Patent: July 19, 2005Assignee: The Regents of the University of MichiganInventors: James Varani, Gary J. Fisher, John J. Voorhees, Sewon Kang
-
Patent number: 6911473Abstract: The present invention relates to a composition comprising an organic preservative acid and a UV-active indicator substance for preserving wood and for detection of the sufficient preservation of wood.Type: GrantFiled: November 27, 2002Date of Patent: June 28, 2005Assignee: Nutrinova Nutrition Specialties & Food Ingredients GmbHInventors: Nico N. Raczek, Ariane Wetzel
-
Patent number: 6852878Abstract: Thioketals and thioethers are provided that inhibit the expression of VCAM-1, and which can be used in the treatment of VCAM-1 mediated diseases including inflammatory disorders, cardiovascular diseases, occular diseases, autoimmune diseases, neurological disorders, and cancer. The compounds also can be used to treat hyperlipidemia and/or hypercholesterolemia.Type: GrantFiled: March 21, 2001Date of Patent: February 8, 2005Assignee: Atherogenics, Inc.Inventors: Charles Q. Meng, Lee K. Hoong, Patricia K. Somers
-
Patent number: 6835749Abstract: Sulfohydroxamic acid diarylamines and derivatives thereof; compositions made from them; and methods of using them.Type: GrantFiled: September 13, 2002Date of Patent: December 28, 2004Assignee: Warner Lambert CompanyInventor: Haile Tecle
-
Patent number: 6814977Abstract: The present invention is directed to a formulation comprising a lipid-regulating agent dissolved in at least one medium chain glycerol ester of a fatty acid as the primary solvent medium for said agent. One or more emulsifiers may be added to the formulation.Type: GrantFiled: December 18, 1998Date of Patent: November 9, 2004Assignee: Abbott LaboratoriesInventors: John M. Lipari, Dawn M. Raymond, Tom Reiland
-
Patent number: 6803057Abstract: An acidic aqueous hydrogen peroxide solution is provided with improved disinfectant activity. Concentrated solutions preferably contain up to about 8 wt./wt. % H2O2 and as-used concentrations contain about 0.5% wt./wt. % H2O2. The solution also contains from 0.05 to 8.0 wt./wt. % of at least one phosphorous-based acid, e.g. phosphoric acid and/or a phosphonic acid with from 1 to 5 phosphonic acid groups, and from 0.02 to 5 wt./wt. % of at least one anionic surfactant. The surfactant is selected from C8 to C16 alkyl aryl sulfonic acids, sulfonated C12 to C22 carboxylic acids, C8 to C22 alkyl diphenyl oxide sulfonic acids, naphthalene sulfonic acids, C8 to C22 alkyl sulfonic acids, and alkali metal and ammonium salts thereof, and alkali metal C8 to C18 alkyl sulfates, and mixtures thereof. Most preferably the solution has an emulsifier and/or hydrotrope, e.g. an alkylated sulfonated diphenyl oxide salt, an alkyl aryl polyoxyethylene surfactant, and/or a polyoxyethylene surfactant.Type: GrantFiled: December 28, 2001Date of Patent: October 12, 2004Assignee: Virox Technologies Inc.Inventors: Jose A. Ramirez, Michael J. Rochon
-
Patent number: 6800605Abstract: New thyroid receptor ligands are provided which have the general formula in which: X is —O—, —S—, —CH2—, —CO—, or —NH—; Y is —(CH2)n— where n is an integer from 1 to 5, or cis- or trans-ethylene; R1 is halogen, trifluoromethyl, or alkyl of 1 to 6 carbons or cycloalkyl of 3 to 7 carbons; R2 and R3 are the same or different and are hydrogen, halogen, alkyl of 1 to 4 carbons or cycloalkyl of 3 to 6 carbons, at least one of R2 and R3 being other than hydrogen; R4 is hydrogen or lower alkyl; R5 is hydrogen or lower alkyl; R6 is carboxylic acid, or esters or prodrugs; R7 is hydrogen or an alkanoyl or an aroyl. In addition, a method is provided for preventing, inhibiting or treating a disease associated with metabolism dysfunction or which is dependent upon the expression of a T3 regulated gene, wherein a compound as described above is administered in a therapeutically effective amount.Type: GrantFiled: January 16, 2001Date of Patent: October 5, 2004Assignee: Bristol-Myers Squibb CompanyInventors: Todd J. Friends, Denis E. Ryono, Minsheng Zhang
-
Patent number: 6797728Abstract: Pulmonary surfactant is required in order to reduce surface tension in the lungs so that less effort is needed to reinflate the lungs after exhalation. A number of diseases and conditions exist that disrupt the normal flow of surfactant secretion, resulting in respiratory distress or failure. The present invention provides a method of treating a patient in respiratory distress syndrome wherein a surfactant deficiency has occurred, thereby restoring a normal respiratory function.Type: GrantFiled: November 7, 2001Date of Patent: September 28, 2004Assignee: Thomas Jefferson UniversityInventor: David S. Strayer
-
Patent number: 6787528Abstract: The compounds of formula (I) are hydrophilic aryl phosphate, thiophosphate, and aminophosphate intestinal apical membrane Na-mediated phosphate co-transportation inhibitors. The compounds can be administered orally, where they act to inhibit Na-dependent phosphate uptake in the intestines, or internally, where they interact with the phosphate control functions of the kidneys and parathyroid. They are therefore useful for inhibiting sodium-mediated phosphate uptake, reducing serum PTH, calcium, calcitriol, and phosphate, and treating renal disease in an animal, including a human.Type: GrantFiled: January 7, 2002Date of Patent: September 7, 2004Assignee: Board of Regents, The University of Texas SystemInventor: Brian E. Peerce
-
Patent number: 6787573Abstract: The invention relates to the field of antiviral agents, and more specifically to antiviral therapy. The invention provides use of at least one compound or mixture of compounds of the general formula or a functional equivalent or pharmaceutically acceptable salt or hydrate thereof for the production of a pharmaceutical composition for the treatment of a viral infection.Type: GrantFiled: March 14, 2002Date of Patent: September 7, 2004Assignees: Universiteit Utrecht, Universitair Medisch Centrum UtrechtInventor: Johannes Servatius Leonardus Maria Nottet
-
Publication number: 20040157931Abstract: The present invention relates to an improved acid disinfectant composition which exhibits excellent bactericidal activity against a wide spectrum of Gram-negative and Gram-positive bacteria.Type: ApplicationFiled: January 6, 2004Publication date: August 12, 2004Inventors: Jeong Chan Ra, Kyung Sun Kang, Yong Ho Park, Yong Soon Lee, Hae Jung Han, Jong Eun Lee
-
Patent number: 6749869Abstract: The mastitis control teat dip composition of the invention provides rapid initial kill, a useful highly pseudoplastic rheology, a barrier/film-forming capacity, a unique antimicrobial composition that is stable over an extended period of time, and unexpected long term microbial control when compared to the prior art materials disclosed in patents and used in the marketplace. The compositions of the invention are made by combining an aqueous thickened liquid composition containing the organic components which can be combined with a simple aqueous solution of a salt of chlorous acid, preferably an alkali metal chlorite. The materials can be combined, blended into a smooth viscous material and can be immediately contacted with the target animals. The compositions of the invention provide rapid initial kill, consistent long term kill and chemical and rheological stability.Type: GrantFiled: September 26, 1997Date of Patent: June 15, 2004Assignee: EcolabInventors: Francis L. Richter, Cathy M. Paquette, Richard K. Staub
-
Patent number: 6723750Abstract: Method for treating dermal pre-melanoma conditions which include administering an effective amount of a photosensitive agent to a dermal pre-melanoma cell and activating the photosensitive agent, thereby treating a dermal pre-melanoma condition.Type: GrantFiled: March 15, 2002Date of Patent: April 20, 2004Assignee: Allergan, Inc.Inventor: Martin A. Voet